Colchicine an effective and cheap medication to reduce MACE
Cardiac events are a huge burden in field of medicine. A recent study showed that colchicine significantly reduces MACE risk in coronary artery disease (CAD) patients who underwent percutaneous coronary intervention (PCI). Colchicine reduced the risk of repeat vessel revascularization, stent thrombosis, and stroke. The study appears in the BMJ journal Open Heart.
PCI is the preferred coronary reperfusion strategy that induces endothelial trauma which may scale an inflammatory response. This may increase the likelihood of further major adverse cardiovascular events (MACE). Colchicine is a cheap and widely used anti-inflammatory that has shown promise in improving cardiovascular outcomes.
For more information check out the full story on the link below:
Colchicine Cheap And Low-Risk Medication To Reduce MACE In Patients Undergoing PCI: BMJ
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.